References
- Proven A, Gabriel SE, Orces C, O’Fallon M, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–708
- Van der Veen MJ, Dinant HJ, Van Booma-Frankfort C, Van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatic and giant cell arteritis? Ann Rheum Dis 1996;55:218–223
- Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheum 2001;19:495–501
- Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106–114
- Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, Monetcucco C. Prednisone plus methotrexate for polymyalgia rheumatic: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141–493–500
- Weyand CM. The Dunlop-Dottridge Lecture: the pathogenesis of giant cell arteritis. J Rheumatol 2000;27:517–522
- Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;98:1642–1649
- Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC. Tissue production of pro-inflammatory cytokines (IL-1B, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004;43:294–301
- Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatic and giant cell arteritis. Arthritis Rheum 1993;36:1286–1294
- Visvanathan S, Rahman MU, Hoffman GS, Xu S, Garcia-Martinez A, Segarra M, Lozano E, Espigol-Frigole G, Hernandez-Rodriguez J, Cid MC. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. Rheumatology 2011;50:2061–2070
- National Institute for Health and Care Excellence. (2007 Oct 24). TA130 Rheumatoid arthritis—adalimumab, etanercept and infliximab: guidance. Retrieved from http://guidance.nice.org.uk/TA130/Guidance/pdf/English
- US Food and Drug Administration. (1999 Nov 10). Infliximab Product Approval Info—Licensing Action. Retrieved from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093335.htm
- US Food and Drug Administration. (2002 Dec 31). Adalimumab Product Approval—Licensing Action. Retrieved from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm
- National Institute for Care and Health Excellence (2011 Jun 22). TA225. Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs)—golimumab: guidance. Retrieved from http://www.nice.org.uk/guidance/TA225/Guidance/pdf
- U.S Food and Drug Administration. (2009 Apr 24). Drug Approval Package: Simponi (Golimumab) Injection. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125289s0000TOC.cfm
- National Institute for Care and Health Excellence. (2010 Feb 24). TA186. Rheumatoid arthritis—certolizumab pegol: guidance. Retrieved from http://guidance.nice.org.uk/TA186/Guidance/pdf/English
- US Food and Drug Administration. (2008 Apr 28). Drug Approval Package: Cimzia (Certolizumab Pegol) Injection. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm
- US Food and Drug Administration. (1998 Dec 2). Etanercept Product Approval Information. Retrieved from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–1563
- Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933–2935
- Torrente SV, Guerri RC, Perez-Garcia C, Benito P, Carbonell J. Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha. Intern Med 2007;37:280–281
- Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006;25:109–110
- Airo P, Antonioli CM, Vianelli M, Toniati P. Antitumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology 2002;41:347–349
- Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant-cell arteritis. Ann Intern Med 2007;146:621–630
- Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353–1355
- Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373–374
- National Institute of Health and Care Excellence. (2008 May 28). TA143. Ankylosing spondylitis—adalimumab, etanercept and infliximab: guidance. Retrieved from http://guidance.nice.org.uk/TA143/Guidance/pdf/English
- National Institute of Health and Care Excellence. (2010 May 29). TA187. Crohn’s disease—infliximab (review) and adalimumab (review of TA40): guidance. Retrieved from http://guidance.nice.org.uk/TA187/Guidance/pdf/English
- National Institute of Health and Care Excellence. (2008 Jun 25). TA146. Psoriasis—adalimumab: NICE guidance. Retrieved from http://guidance.nice.org.uk/TA146/Guidance/pdf/English
- National Institute of Health and Care Excellence. (2010 Aug 25). TA199. Psoriatic arthritis—etanercept, infliximab and adalimumab: guidance, Retrieved from http://guidance.nice.org.uk/TA199/Guidance/pdf/English
- US Food and Drug Administration. (2011 Dec). Humira (adalimumab) label. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf
- US Food and Drug Administration. (2012 Sep 28). FDA approves Humira to treat ulcerative colitis. Retrieved from http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm321650.htm
- Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, Maurier F, de Wazieres B, Quéméneur T, Ravaud P, Mariette X. Clinical and epidemiological research: extended report: adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis Epub ahead of print 29 July 2013. doi: 10.1136/annrheumdis-2013-203586
- Leydet-Quilici H, Luc M, Armingeat T, Pham T, Lafforgue P. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 2007;74:303–304
- Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 2004;31:1467
- US Food and Drug Administration. (2008 Apr 28). FDA approves cimzia to treat Crohn’s disease. Retrieved from http://www.fda.gov/newsevents/newsroom/pressannouncements/2008/ucm116882.htm
- National Institute of Health and Care Excellence. (2011 Aug 24). TA233. Ankylosing spondylitis—golimumab: guidance. Retrieved from http://guidance.nice.org.uk/TA233/Guidance/pdf/English
- National Institute of Health and Care Excellence. (2011 Apr 27). TA220. Psoriatic arthritis—golimumab: guidance. Retrieved from http://guidance.nice.org.uk/TA220/Guidance/pdf/English
- US Food and Drug Administration. (2013 Nov). Full Prescribing Information: Golimumab. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125289s094lbl.pdf
- Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286–1294
- Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041–1048
- Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720–1729
- Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013;45:357–363
- National Institute for Health and Care Excellence. (2011 Dec 14). TA238. Arthritis (juvenile idiopathic, systemic)—tocilizumab: guidance. Retrieved from http://guidance.nice.org.uk/TA238/Guidance/pdf/English
- National Institute for Health and Care Excellence. (2012 Feb 22). TA247. Rheumatoid arthritis—tocilizumab (rapid review TA198): guidance. Retrieved from http://guidance.nice.org.uk/TA247/Guidance/pdf/English
- Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, Amano K. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 2012;31:569–574
- Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol 2012;31:1263–1265
- Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, Zwerina J. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011;70:1874–1875
- Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep Epub ahead of print 2011 Jun 30. doi: 10.1136/bcr.04.2011.4135
- Isik M, Kilic L, Dogan I, Calguneri M. Tocilizumab for giant cell arteritis: an amazing result. Rheumatol Int 2013;33:2961–2962
- Lurati A, Bertani L, Re KA, Marrazza M, Bompane D, Scarpellini M. Successful treatment of a patient with giant cell vasculitis (horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Rep Rheumatol 2012;2012:639612
- Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51:151–156
- Schafer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 2012;24:31–37
- Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011;38:2080–2081
- Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156
- Vinit J, Bielefeld P, Muller G, Besancenot JF. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012;79:317–318
- Villiger PM, Seitz M. (2013 Oct). Tocilizumab for Patients with Giant Cell Arteritis. ClinicalTrials.gov. Retrieved from http://clinicaltrials.gov/show/NCT01450137
- Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, Stone JH. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013;2013:912562
- Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013;25:3–9
- Shepard J, Nicklin M. Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation 2005;111:3135–3140
- Ly K-H, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine 2013. doi: 10.1016/j.jbspin.2013.06.004
- Bhatia A, Ell PJ, Edwards JCW. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005;64:1099–1100